About Haemato AG

Company Description

HAEMATO has been committed for over 15 years as a pharmaceutical manufacturer and wholesaler to actively contributing to cost reduction in the healthcare sector, so that every patient can benefit from the latest therapies and treatment concepts, even if these are often very expensive. In addition, the Group focuses on the development and distribution of own brands in the Lifestyle & Aesthetics segment.

HAEMATO covers chronic diseases and high-priced therapies in particular with its own product portfolio. The focus is on the five therapeutic areas of HIV/AIDS, neurology, oncology, rheumatology and ophthalmology. These therapeutic areas include innovative, patent-protected drugs as well as biosimilars and generics. The product portfolio is rounded off with narcotics, which also include cannabis products.

Year founded

1993

Served area

Worldwide

Headquarters

Lilienthalstraße 3a, 12529 Schoenefeld – Germany

Filings & Publications

2021

Report Q1 H1 Q3 FY
Consolidated Report ENG
Corporate Governance Report
Company Presentation
General Presentation
Sustainability Report
Remuneration Report

2022

Report Q1 H1 Q3 FY
Consolidated Report ENG
Corporate Governance Report
Company Presentation
General Presentation
Sustainability Report
Remuneration Report

Insider Trades

Sign up and we will inform you!

Shareholder information

Shares outstanding

5,230,000

IPO

Dec. 5, 2005

Stock exchange(s)

Frankfurt Stock Exchange

Contact Investor Relations department

Stay up to date

Keep yourself informed with the most recent updates on FinancialReports, IPOs, product advancements, and other significant news.